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Deep brain stimulation (DBS) emerged in the late 1960s as a possible therapeutic alter-
native to lesioning in patients with severe, chronic, intractable pain. DBS devices in the
era were based on cardiac pacing technology but were greatly modiﬁed in implementa-
tion due to the unique needs of DBS. Clinical studies in the 1970s and early 1980s have
revealed a technique with modest results which did not lead to regulatory approval for
the treatment of pain. In the 1980s a new application for DBS emerged in the treatment
of movement disorders. Clinical trials conﬁrmed the robustness of the therapy leading
to approvals by regulatory authorities in the US and Europe for the treatment of tremor
and the symptoms of Parkinson’s disease. Technology based on that used for earlier clin-
ical research in pain was improved by leveraging advances in cardiac pacing technology
resulting in the sophisticated and reliable systems available today. In the 1990s scientiﬁc
exploration began in the treatment of psychiatric disorders which is ongoing today. Simul-
taneously, studies into the treatment of epilepsy were begun which resulted in regulatory
approval in Europe. Suggestions have been made to expand these scientiﬁc explorations
to other central nervous system dysfunctions. Opportunity remains to improve the tech-
nology including individualized and symptom speciﬁc stimulation patterns, more physician
and patient friendly programming, and possibly closed-loop systems for more situation
dependent and effective therapy.
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INTRODUCTION
Neurostimulation is amethod applied to treat variousneurological
disorders including chronic pain,urinary incontinence, andmove-
ment disorders. The vast experience with active implantable tech-
nology in cardiac stimulation has been evolved successfully into
the development of neurostimulators and applications for chronic
neurological and gastro-urological diseases. Major developments
have been achieved through ongoing collaboration and partner-
ship between academia and medical device industry. More than
80,000 patients have been treated with DBS worldwide through
the end of 2010. The aim of this article is to provide an overview
of the history, present status, and potential future developments
of deep brain stimulation (DBS).
NOTICE
This article discusses current developments and future possibilities
for DBS therapies. Three companies, Medtronic, Inc. (Minneapo-
lis, MN, USA), St Jude Medical (St. Paul, MN, USA), and Boston
Scientiﬁc (Natick, MA, USA) have developed DBS systems cur-
rently at various stages of regulatory evaluation and approval. The
authors wish to emphasize that the only Medtronic DBS systems
approved by regulatory authorities in Europe and the US are for
the following therapies:
• Essential Tremor: CE Mark; FDA approval
• Symptomsof Parkinson’sDisease (PD):CEMark; FDAapproval
• Dystonia: CE Mark; Humanitarian Device Exemption (HDE)
in US
• Obsessive Compulsive Disorder (OCD): CE Mark; HDE in US
• Epilepsy: CE Mark
Refer to the product labeling packaged with Medtronic DBS prod-
ucts for speciﬁc indications, contraindications, warnings, precau-
tions, adverse events summary, and patient selection. Refer to the
product labeling of St Jude Medical and Boston Scientiﬁc for the
speciﬁc regulatory status of these systems.
DBS HISTORY AND CURRENT STATE
With new ﬁndings on the pathophysiology and neuroanatomy
of thalamocortical–basal ganglia neural circuits in neurological
and psychiatric disorders, Neurosurgeons, Neurologists, and Psy-
chiatrists have explored DBS targets in regions that correspond
to traditional lesional targets. At ﬁrst, DBS was considered to
be “reversible lesioning.” Further investigations, however, sug-
gested that stimulation-induced modulation of brain activities
may rather be the mechanism of action (Kringelbach et al., 2007).
During the evolution of DBS in the treatment of pain, movement
disorders, epilepsy, and psychiatric disorders, industry has worked
hand-in-hand with physicians to develop these therapies.
PAIN
The ﬁrst evidence of physician/industry collaboration on DBS
came in 1969 when Hosobuchi approached Medtronic, Inc. to
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design and build a system to stimulate the ventral posterior medial
(VPM) nucleus of the thalamus in a patient with severe intractable
facial pain (Hosobuchi et al., 1973). Today,DBS for pain is utilized
in a small number of centers who report positive results in a highly
selected patient population (Owen et al., 2007).
MOVEMENT DISORDERS
In 1987, Siegfried and Benabid independently reported suppres-
sion of severe, intractable tremor by stimulation of the ventral
intermediate (Vim) nucleus of the thalamus (Benabid et al., 1987,
1991, 1993; Siegfried and Shulman, 1987). Although there were
earlier reports of stimulation suppressing involuntary movements
in the context of treating pain, these were the ﬁrst reports of
chronic DBS speciﬁcally for the treatment of movement disorders.
Subsequently, Benabid collaborated with Medtronic on the devel-
opment of DBS for treating patientswith severe, intractable tremor
which culminated in a multicenter clinical trial and regulatory
approval for the therapy. In 1994, Siegfried reported improvement
of multiple symptoms of PD by stimulation of the globus pal-
lidus internal (GPi; Siegfried and Lippitz, 1994). In 1993, Benabid
extended this work to stimulation of the sub-thalamic nucleus
(STN) in patients with PD (Limousin et al., 1995). Clinical stud-
ies in North America and Europe resulted in regulatory approvals
for these two indications (Limousin et al., 1999; The Deep Brain
Stimulation for Parkinson’s Disease Study Group, 2001). Later
clinical studies conﬁrmed the early data with evidence Level 1
results (Deuschl et al., 2006; Weaver et al., 2009; Williams et al.,
2010).
Deep Brain Stimulation has been explored for treating other
movement disorders, most notably dystonia with stimulation in
the GPi (Coubes et al., 2000; Kupsch et al., 2006; Mueller et al.,
2008; Vidailhet et al., 2009). Studies are ongoing for DBS in the
treatment of cervical dystonia (Krauss et al., 1999), tardive dys-
tonia (Trottenberg et al., 2001; Gruber et al., 2009), Gilles de la
Tourette syndrome (Temel and Visser-Vandewalle, 2004; Porta
et al., 2009; Hariz and Robertson, 2010), and other movement
disorders.
EPILEPSY
Velasco et al. (1987) reported favorable results with stimula-
tion of the centromedian nucleus of the thalamus with DBS. In
2002, Lozano reported seizure reduction with DBS of the anterior
nucleus (AN) of the thalamus (Hodaie et al., 2002). This led to a
multicenter, double blind, randomized industry sponsored clinical
trial of DBS of the AN in patients with refractory epilepsy which
resulted in regulatory approval for the therapy in Europe. Fisher
et al. (2010) concluded that bilateral DBS of the AN is useful in
medically refractory partial and secondarily generalized seizures
while the complication rates are modest. However, in the US, the
FDA continues to review the data for risk beneﬁt and approval for
the therapy has not yet been granted. Meanwhile, Boon conducted
pilot studies of amygdalohippocampal stimulation in temporal
lobe epilepsy (Vonck et al., 2002; Boon et al., 2007). These stud-
ies are ongoing. A second industry sponsored clinical study is
currently underway which evaluates the effect of stimulation of
the seizure focus with a device capable of either surface or depth
stimulation (NeuroPace, Mountain View, CA, USA).
PSYCHIATRIC DISORDERS
In 1999, Nuttin proposed stimulation of the internal capsule (IC)
as an alternative to irreversible capsulotomy in the treatment of
OCD opening the gateway for exploration of DBS in psychiatric
disorders (Nuttin et al., 1999). Early mixed results led to a rede-
ﬁnition of the target as the area just ventral to the IC (ventral
capsule/ventral striatum, VC/VS) and/or the nucleus accumbens
(NA; Sturm et al., 2003; Denys et al., 2010; Greenberg et al., 2010).
A French multicenter study explored the effects of DBS in the
associative limbic part of the STN (Mallet et al., 2008). Obser-
vations that OCD patients treated with DBS in the region of the
ventral striatum showed reduced depression led teams in North
America and Europe to explore the use of DBS in the treatment of
severely refractory depression patients (Malone et al., 2009; Bew-
ernick et al., 2010). Studies are ongoing in NorthAmerica, Europe,
and elsewhere on these applications.
Other targets for the treatment of depression disorders under
clinical investigation include the white matter adjacent to Brod-
mann Area 25 in the subgenual cingulated cortex (Cg25; Mayberg
et al., 2005; Hamani et al., 2011), the ventral caudatum (Aouizer-
ate et al., 2009), and the lateral habenula (Sartorius et al., 2010).
Very recently the lateral branch of the medial forebrain bundle has
been hypothesized to represent an alternative target (Coenen et al.,
2010).
Deep Brain Stimulation is currently approved for the treatment
of OCD by stimulation of the VC/VS through the HDE process in
the US and by CE Mark in Europe. Both approvals were based on
limited data and additional studies are ongoing to further clarify
the beneﬁts and limits of the therapy. Major industry sponsored
trials of DBS of theVC/VS andDBS of the Cg25 in the treatment of
depression are now underway. DBS for all other applications and
targets in the treatment of psychiatric disorders is at an exploratory
stage. The scientiﬁc community is concerned to avoid repeating
the errors of a previous era of psychosurgery by proceeding care-
fully and in consultation with experts in ethics (Kringelbach and
Aziz, 2009).
RISKS
Infection is one the most common adverse events reported at
around 2.5% per year of which about one in ﬁve results in the
explant of a portion of the system. Surgical complications are
reported in the 3–4% range. Intracranial hemorrhage is reported
at about 3%, approximately half of which are asymptomatic, a
quarter are transient, and a quarter result in permanent deﬁcit.
Operative mortality is well under 1% (Voges et al., 2007). Hard-
ware failure including lead dislodgement and fracture can also
occur leading to replacement surgery.
Depression, suicidal ideations, and suicide have been reported
in patients receiving DBS for movement disorders although no
direct cause and effect relationship has been established (Witt
et al., 2008). Patients should be assessed preoperatively for risk
and monitored post-operatively for presence of these effects.
ETHICAL CONSIDERATIONS
Other potential therapeutic applications for DBS are numerous
[cluster headache, dementia, addiction, gait disorders, obesity
(Halpern et al., 2008), blood pressure, etc.] The ultimate goal is
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to improve quality of life for patients and their caregivers. While
there is strong evidence for DBS in Parkinson’s disease, essential
tremor, and dystonia, there is still more work needed to extend
the knowledge on therapy efﬁcacy, safety, and cost efﬁciency in
other indications. Therefore it is crucial to conduct well designed
controlled studies in line with the ethical criteria described by
Lipsman et al. (2010). DBS should be used to help restore normal
function and provide relief from distress and should never be used
for augmentation or brain enhancement (Kringelbach and Aziz,
2009). The potential beneﬁt should always be balanced with the
potential risk for surgical or stimulation-induced adverse events.
DESIGN AND BUILD OF DEVICES
The components of implantable DBS systems include the neu-
rostimulator, extensions, lead, and electrodes and the external
components such as physician programmer, patient programmer
(Figure 1), and a recharger for rechargeable devices.
When Hosobuchi approached Medtronic in 1969 to build a
DBS system, cardiac pacing technology, the basis of the industry,
utilized mercury zinc batteries housed in large devices with simple
circuits. Clearly to deliver a pulse train of up to 100 pulses per sec-
ond (pps) at the therapeutic voltage and pulse width required for
neurostimulation demanded an alternative approach. Thus, the
ﬁrst DBS systems were radio frequency devices. The electrode was
implanted at the appropriate brain target and cabled to a passive
radio frequency receiver powered froma transmitter carried on the
patient’s belt. The transmitter was coupled to the implanted device
with an antenna taped to the patient’s skin over the implanted
receiver.
Over the following two decades, improvements in power
sources and circuit efﬁciencies in cardiac pacing were adapted for
neurostimulation devices. The advent of lithium battery technol-
ogy for implantable applications led to the possibility for neu-
rostimulators to be fully implantable by the end of the 1980s,
thereby reducing the dependence on the patient to care for and
manage an external device. Implantable devices are programmed
by a physician programmer. The programmer communicates with
the electronics of the implanted device using pulse-width and/or
pulse interval-modulated encoding of an inductively coupled
carrier frequency.
In addition, improvements to circuit efﬁciency and capabil-
ity have allowed for the development of dual channel devices
capable of powering two four-contact leads. A new genera-
tion of devices provides increased parameter variability thus
allowing the physician to tailor the stimulation to meet the
topography and nature of the patient’s symptoms with the aim
to optimize therapeutic outcome while minimizing side effects
(Wojtecki et al., 2011). A new generation of silver vanadium
oxide batteries has been developed to meet these increased power
requirements.
Commercial stimulators use charge-balanced stimulation
resulting in zero net ﬂowof charge to avoid deleterious effects. Dif-
ferent electrode conﬁgurations can be programmed for monopo-
lar and bipolar stimulation. Based on the speciﬁc therapy appli-
cation the parameters can be adjusted over a range of 0–10.5V,
60–450μs, and 2–250 pps (Testerman et al., 2006). Typical stimu-
lation parameters for DBS for currently approved therapies such
as movement disorders are in the range of 2–4V (2–4mA for a
FIGURE 1 | Deep Brain Stimulator SystemType Activa®PC (primary cell).The patient programmer may perform device status interrogation (e.g., power
status, program group, battery status, and on/off function).
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DBS electrode impedance of 1000 Ω) 90–180μs pulse width, and
100–185 pps.
Due to the wide range of parameters in a neurostimulator, the
battery life can vary considerably. For movement disorder applica-
tions, typical battery life expectation ranges from2 to 5.5 years. For
psychiatric applications, battery life may be considerably shorter
due to the larger electrode surface areas and voltage levels required.
The expected life can be from under 1 to 1.5 years although these
numbers have been increasing as the targeting of the electrode
contact has been reﬁned.
The recent development of implantable rechargeable batter-
ies has allowed physicians to provide DBS therapy to patients
with higher energy requirements. Expected time-to-replacement
is increased with the use of rechargeable DBS neurostimulators to
9 years. The aim of these developments is to improve patient com-
fort, reduce frequency of replacement surgeries, increase safety and
efﬁcacy, and to improve cost–beneﬁt ratio of the therapy.However,
recharging a neurostimulator requires patient cooperation and the
patient’s ability to comply should be considered before selecting
this option.
Simultaneously, improvements have been made to the elec-
trode systems. Today’s electrodes are ﬂexible, yet durable, and are
conﬁgured to meet the anatomical requirements of the area to be
stimulated. Pathological ﬁndings in the brains of eight Parkinson’s
disease patients treated with DBS showed only mild gliosis around
the lead track. The authors concluded that chronic DBS does not
cause damage to adjacent brain tissue (Haberler et al., 2000).
The description of the DBS implantation procedure would
expand the scope of this article beyond its intent. How-
ever, it is important to point out that the surgery requires a
multidisciplinary team. It involves several steps from mounting
the stereotactic frame to implanting the DBS neurostimulator
(Figure 2). Recent ﬁndings from a study on Parkinson’s dis-
ease patients suggest that frameless implantation of DBS leads
compared to frame based technique may result in compara-
ble clinical outcome when performed by an experienced team
(Brontë-Stewart et al., 2010).
FUTURE DEVELOPMENTS
The ultimate goal of new technologies and developments is to
improve patient outcome, reduce clinical burden, and reduce
dependency on the patient to manage the device. Any new medical
device requires the balance of three key elements: unmet medical
or user need, technical feasibility (including safety and reliability),
and scientiﬁc veriﬁcation.
Several areas to consider are:
• The ability to steer the electrical ﬁeld around the electrodes will
be an advantage in optimization providing some forgiveness in
electrode location while still allowing the physician to optimize
the therapy post-operatively.
• Exploration of alternatives to the ﬁxed rate pulse train may
improve efﬁcacy and/or decrease potential for adaptation over
time. These alternatives could include amplitude, frequency, or
pulse-width modulation and intermittent stimulation.
• Many patients with chronic neurological diseases are at a point
in their life where interacting with a medical device can be
confusing. Making that interaction simpler and more obvious
is a continuing challenge for the industry.
• MRI safe systems will provide a great advantage to the physician
in the ongoing care of these patients.
• Work will continue to explore how to identify and use biomark-
ers, e.g., local ﬁeld potentials, for closed-loop neurostimulators
to provide intelligent DBS therapies (Stanslaski et al., 2009).
FIGURE 2 | Deep Brain Stimulator requires an multidisciplinary expert team and is a multi-step procedure involving stereotactic frame mounting (or
“frameless” tools fixation); imaging, neurophysiological assessment, target verification prior to the DBS lead, and DBS system implantation.
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CONCLUSION
Deep Brain Stimulation is a novel technique which has shown
beneﬁcial results in individual patients in several central nervous
system disorders including pain, movement disorders, psychiatric
disorders, and epilepsy.DBS therapy andproduct development has
depended on a close collaboration between industry and physi-
cian pioneers in the ﬁelds of interest. Today DBS for the treatment
of essential tremor and the symptoms of PD is approved by the
regulatory authorities in the US and Europe. DBS for the treat-
ment of dystonia, and OCD is CE Mark approved in Europe
and through the HDE process in the US. DBS for the treatment
of epilepsy is approved in Europe but remains unapproved in
the US.
The nervous system plays a role in the control of every body
function and, as a result, it is tempting to think that DBS could
play a role in all medical dysfunction. Industry and physicians
must be careful to select those potential applications of DBS that
will bring maximum value to patients and must be committed
to fully respect and comply with all applicable rules and regula-
tions in the therapy development process and particularly in the
conduct of clinical studies.
DISCLAIMER
The reader will note that the authors are associated with
Medtronic, Inc. as employe and consultant. This paper contains
information which discusses uses of DBS that have not been
approved by regulatory agencies. Medtronic does not market its
products for unapproved indications and can make no represen-
tations regarding the safety and/or efﬁcacy of the devices if used
for unapproved claims.
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